-
Published on 1 May 2017
BioMarin Pharmaceutical Inc (BMRN) just got good news from the FDA for a treatment of an ultra-rare
disorder. But with a price tag of $702,000 a year, is a drug price
debate waiting in the wings? Jim Cramer spoke with the CEO for his take.
» Read more about BioMarin here: http://cnb.cx/2pH4PDI
"Mad Money" takes viewers inside the mind of one of Wall Street's most respected and successful money managers. Jim Cramer is your personal guide through the confusing jungle of Wall Street investing, navigating through both opportunities and pitfalls with one goal in mind -- to try to help you make money.
About CNBC: From 'Wall Street' to 'Main Street' to award winning original documentaries and Reality TV series, CNBC has you covered. Experience special sneak peeks of your favorite shows, exclusive video and more.
No comments:
Post a Comment